A molecular diagnostic developed by MDxHealth of Belgium will be used to screen patients for a second oncology trial in what is seen as a further expansion of the rapidly evolving field of personalised medicine. The assay tests methylation status. ---Subscribe to MedNous to access this article--- Company News Research & University News
